**Name of journal:** ***World Journal of*** ***Gastroenterology***

**Manuscript NO: 33686**

**Manuscript Type: MINIREVIEWS**

**Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology**

Dubois-Camacho K *et al.* Glucocorticosteroid therapy in IBD

Karen Dubois-Camacho, Payton A Ottum, Daniel Franco-Muñoz, Marjorie De la Fuente, Alejandro Torres-Riquelme, David Díaz-Jiménez, Mauricio Olivares-Morales, Gonzalo Astudillo, Rodrigo Quera, Marcela A Hermoso

**Dubois-Camacho Karen, Franco-Muñoz Daniel, Torres-Riquelme Alejandro, De la Fuente Marjorie, Díaz-Jiménez David, Olivares-Morales Mauricio, Astudillo Gonzalo, Marcela A Hermoso,** Innate Immunity Laboratory, Immunology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago 8380453, Chile

**Ottum Payton A,**Neuroimmunology Laboratory, Immunology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago 8380453, Chile

**De la Fuente Marjorie,**Division of Research, Clínica Las Condes, Santiago 7591046, Chile

**Quera Rodrigo,** Gastroenterology Department, Inflammatory Bowel Disease Program, Clínica Las Condes, Santiago 7591046, Chile

**Author contributions:** All authors equally contributed to literature review, critical revision and editing, and approval of the final version.

**Supported by** National Fund for Scientific and Technological Development No. 1170648 (MHR); línica Las Condes Academic Project PI2013-B002, UApoya No. 560959 (RQ); National Commission for Scientific and Technological Research scholarship No. 21150264 (DDJ), No. 21120682 (MOM); and MECESUP Scholarship No. UCH 0714 (KDC).

**Conflict-of-interest statement:** No potential conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Correspondence to:** **Marcela A Hermoso, PhD,** **Associate Professor,** Innate Immunity Laboratory, Immunology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Independencia 1027, Santiago 8380453, Chile. mhermoso@med.uchile.cl

**Telephone:** +56-2-29785672

**Fax:** +56-2-29786979

**Received:** February 25, 2017

**Peer-review started:** February 28, 2017

**First decision:** April 28, 2017

**Revised:** May 25, 2017

**Accepted:** July 4, 2017

**Article in press:**

**Published online:**

**Abstract**

Inflammatory bowel diseases (IBDs), such as ulcerative colitis and Crohn’s disease, are chronic pathologies associated with a deregulated immune response in the intestinal mucosa, and they are triggered by environmental factors in genetically susceptible individuals. Exogenous glucocorticoids (GCs) are widely used as anti-inflammatory therapy in IBDs. In the past, patients with moderate or severe states of inflammation received GCs as a first line therapy with an important effectiveness in terms of reduction of the disease activity and the induction of remission. However, this treatment often results in detrimental side effects. This downside drove the development of second generation GCs and more precise (non-systemic) drug-delivery methods. Recent clinical trials show that most of these new treatments have similar effectiveness to first generation GCs with fewer adverse effects. The remaining challenge in successful treatment of IBDs concerns the refractoriness and dependency that some patients encounter during GCs treatment. A deeper understanding of the molecular mechanisms underlying GC response is key to personalizing drug choice for IBDs patients to optimize their response to treatment. In this review, we examine the clinical characteristics of treatment with GCs, followed by an in depth analysis of the proposed molecular mechanisms involved in its resistance and dependence associated with IBDs. This thorough analysis of current clinical and biomedical literature may help guide physicians in determining a course of treatment for IBDs patients and identifies important areas needing further study.

**Key words:** Inflammatory bowel diseases; Ulcerative colitis; Crohn’s D ﷽﷽﷽﷽﷽﷽﷽﷽ove fewer side effects, but those effects are of sed levels of B-gal when miR-378a-disease; Glucocorticoid dependence; Glucocorticoid resistance

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Glucocorticoids are widely used in patients with Inflammatory Bowel Diseases who have moderate or severe disease activity; however, some of them do not respond to treatment or become dependent. Knowledge of both the clinical approach of glucocorticoids eatment as well as the molecular basis underlying their effects will help physicians prescribe drugs that will lead to better outcomes for patients.

Dubois-Camacho K, Ottum PA, Franco-Muñoz D, De la Fuente M, Torres-Riquelme A, Díaz-Jiménez D, Olivares-Morales M, Astudillo G, Quera R, Hermoso MA. Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology. *World J Gastroenterol* 2017; In press

**INTRODUCTION**

Inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn's disease (CD), are multifactorial disorders comprised of both environmental and genetic factors. Even though they are different disease entities, UC and CD are grouped under the generic term of IBDs given their similar activity/remission stages, chronicity, immunological pathophysiology and uncertain etiology[1–3]. The prevalence of UC is 505 per 100.000 people in Europe and 249 per 100.000 people in North America, and CD is 322 per 100.000 people in Europe and 319 per 100.000 people in North America[4]. An increased incidence has been reported in some South American and mid-eastern Asian countries such as Chile[5], Brazil[6], Israel[7], and Malaysia[8]. This tendency might be related to the industrialization phenomenon and the influence of environmental risk factors[4].

**IBDS: A MULTIFACTORIAL COMPLEX DISORDER**

Various genetic and environmental factors have been associated with development of IBDs. Polymorphisms in a vast number of genes which impair functions such as lymphocyte activation, autophagy, pathogen sensing, stress response, antigen presentation, and chemotaxis, among others have been described[9]. The presence of such genetic variants may contribute to an imbalance in the immune response and increased predisposition to IBDs[10,11]. Moreover, environmental factors, such as diet, smoking, appendectomy, breastfeeding behavior in childhood, vitamin D deficiency and infections, play key roles in inflammatory manifestations, and have been described as risk factors for IBDs[12,13]. Furthermore, intestinal microbiome composition differs in IBDs patients compared to healthy subjects: IBD patients have a more predominant *Proteobacteria* population and decreased *Firmicutes* and *Bacteroidetes* populations[14,15]. Environmental factors might be involved in creating such imbalance in microbiome composition, and this may give rise to a constant inflammatory antigenic stimulus in the gut that causes chronic inflammation in genetically susceptible individuals[14].

 These multifactorial components involved in the origin and progression of IBDs, has prevented the development of a specific treatment applicable to all patients. Current treatment options seek to diminish inflammation in order to control symptoms and keep the patient in a state of remission or symptom improvement. For example, aminosalicylates (5-asa derivatives) are used to treat mild disease, while immunosuppressants such as azathioprine/6-mercaptopurine and methotrexate, and biological therapy such as anti-TNF antibodies or anti-integrin are prescribed for moderate to severe disease[16]. Finally, glucocorticoids (GCs) are used to achieve, but not to maintain, remission in patients with moderate to severe activity[17].

**GC THERAPY IN IBDs: ADMINISTRATION AND EFFECTIVENESS**

The first study that demonstrated the usefulness of GCs (cortisone) in controlling severe UC attacks was published in 1955[18]. Since the 70s, the first generation of GCs (prednisone, methylprednisolone, hydrocortisone) has been used to induce clinical remission in IBDs patients. However, significant adverse effects have led to the development of second generation GCs (budesonide, budesonide MMX, Beclomethasone dipropionate)[19–21]. A characteristic of GC treatments and their use is summarized in Table 1.

***First generation GCs: more effective than 5-asa and immunomodulatory treatment with significant secondary effects***

Several studies have compared the efficacy and safety of traditional GCs to other treatments by measuring the rates of remission and adverse side effects. Two independent placebo-controlled double-blind randomized trials showed that 47% of active CD patients treated with prednisone (1 mg/kg, ranging from 40-60 mg/d) achieved clinical remission, defined as CDAI score ˂ 150 (for a review on clinical and endoscopy scoring see references 22-24[22–24]), compared to 26% of patients receiving placebo after 4 mo of treatment. Neither sulfasalazine (0.5-1 gr/15kg) nor azathioprine (2-2.5 gr/kg per day) achieved significant effectiveness[25]. Later, a placebo-controlled study showed that high doses of methylprednisolone (12-48 mg/d), sulfasalazine (3 gr/d), or both in active CD patients, were significantly effective compared to the placebo, and patients treated with methylprednisolone (alone or in combination with sulfasalazine) showed faster improvement compared to sulfasalazine[26].

Despite the effectiveness of GCs demonstrated in patients with severe CD, a prospective multicenter study comprised of patients with active CD on prednisone treatment (1mg/kg per day) concluded that while 92% achieved clinical remission, only 29% of them reached endoscopic remission[27]. The presence of stenosis or fistula secondary to CD which occurs in patients who do not reach endoscopic remission, indicates a poor response to GC therapy and requires surgical intervention[27]. This suggests that GCs are efficient in improving the inflammatory response but other strategies are needed to increase mucosal healing.

Regarding UC, systemic GCs are the first choice therapy in cases of severe colitis[3]. In acute and critical UC, 76% of the patients treated with prednisolone (20 mg/d), plus a nightly rectal drip of hydrocortisone succinate sodium (100 mg in solution), presented clinical remission *vs* 52% of patients who were treated with sulfasalazine (8 gr/d the first week, 4 gr/d the second week)[28] demonstrating the clinical efficacy of this treatment. Likewise, two consecutive trials in UC patients with left side colitis determined that oral prednisone (1 mg/kg per day) was effective in severe stages of the disease compared with calcium lactate (1-3 gr; placebo), and prednisone treatment led to clinical remission more quickly and more often than those treated with salazopyrin (4 gr/d; a sulfasalazine derivate) and topic hydrocortisone treatments (100 mg/150 mL of sterile water administered as an enema)[29].

Despite the effectiveness of first generation GCs, they are characterized by several serious side effects that limit their long-term use. Among these, some of the most important are: metabolic (altered distribution of fat, Cushing's face or steroid-induced diabetes), eye-related (cataracts and glaucoma), dermatological (bruising and urticarial), gastrointestinal (gastric ulcer and gastrointestinal bleeding), and musculoskeletal side effects (osteopenia to osteoporosis). Additionally, adverse effects on the central nervous system have been described (insomnia, anxiety, hyperactivity, psychotic processes), along with hypertension, hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections due to immunosuppression[19]. However, its use in IBDs patients has not be associated with atherosclerosis progression[30]. Finally, there is evidence that GC use increases the likelihood of sepsis of gastrointestinal origin; therefore it should be prescribed with caution in these patients[31].

***Second generation GCs***: ***high anti-inflammatory activity and fewer side effects***.

The previously described serious side-effects related to first-generation GCs drove the development of second-generation steroids, which maximize the amount of corticosteroid locally available for distal ileum and proximal colon and minimize systemic bioavailability[3,26]. These new formulations of GCs with limited absorption include budesonide, budesonide MMX (multimatrix delivery system MMX) and beclomethasone dipropionate[3,19].

**Budesonide, similar effectiveness with fewer adverse effects:** Budesonide undergoes hepatic inactivation before reaching the systemic circulation (first-pass metabolism) which reduces its bioavailability[3]. Various placebo-controlled clinical studies have provided evidence about the efficacy of budesonide in IBDs patients. A multicenter randomized, placebo-controlled, double-blind clinical trial was conducted in CD patients who received three different budesonide doses (3, 9 and 15 mg/d)[32]. After 8 wk of treatment, 51% of those receiving 9 mg budesonide progressed to remission in CD patients with ileum and proximal colon disease activity. Thus, this dose was effective and safe but depended on disease location. A randomized, double-blind, double-dummy controlled trial conducted in patients with mild to moderately active CD demonstrated that budesonide (9 mg/d for 2 mo) was as effective as prednisone (40 mg/d for the first 2 wk, 30 mg/d the third week, and gradually tapered to 5 mg/wk at the end of the study lasting 2 mo) in patients with terminal ileum, cecum, and/or ascending colon inflammation[33].

Subsequently, a multicenter double-blind, randomized trial was conducted in CD patients with moderate activity in the distal ileum and ascending colon. More patients that received budesonide (4.5 mg twice daily, or 9 mg once daily) achieved clinical remission compared to placebo 2 weeks after beginning treatment, and this difference was statistically significant[34]. In addition, a pooled analysis of trials in CD patients found significantly fewer GC-related adverse events compared to patients treated with conventional corticosteroids (RR = 0.64, 95%CI: 0.54 - 0.76)[35].

An improved oral formulation of budesonide uses the colonic delivery technology Multi-Matrix System (MMX) to extend drug release in the colon (Budesonide MMX). Due to this characteristic, it is indicated for the treatment of UC patients that do not respond to standard doses of salicylates. A placebo-controlled study demonstrated that a higher proportion of UC patients with mild to moderate activity treated with budesonide MMX (9 mg), reached clinical remission and symptom resolution compared to placebo. In contrast, a lower dose of budesonide MMX (6 mg) and mesalamine, another salicylate treatment (2.4 gr/d), did not significantly improve either parameter[36]. Furthermore, the higher dose of Budesonide MMX was efficient in inducing remission in patients with mild to moderate UC disease who did not achieve remission with 5-ASA treatments such as mesalamine or sulfasalazine[36,37]. Currently, physicians prescribe Budesonide MMX in UC patients that do not respond to traditional maintenance therapy before treating with azathioprine/6-mercaptopurin.

In 2015, data from 5 clinical studies, including double-blind, randomized, and open label studies, showed that rates of adverse effects were similar between budesonide MMX 9 mg and 6 mg (54.5% and 60.6% respectively) and placebo (50.5%) in patients with mild to moderate UC[38]. Furthermore, the open label studies showed less frequency of adverse effects with budesonide MMX (3 mg or 9 mg) compared to placebo. The most common adverse effects in these studies were headache, nausea and urinary tract infection demonstrating that second generation GCs not only have fewer side effects, but those effects are less severe compared to first generation GCs side effects.

**Beclomethasone dipropionate, a second generation option with low systemic activity:** Beclomethasone dipropionate (BDP) is a second-generation corticosteroid with topical effects and minimal systemic activity. It is administered as a pro-drug and is partially metabolized in the lower gastrointestinal tract[39]. The effectiveness and tolerability of BDP versus budesonide have been evaluated in CD patients whose clinical characteristics did not include complications such as stenosis or fistulas. A study showed that BDP (10 mg/d) was less effective than budesonide (9 mg/d) in CD patients treated for 2 mo. They concluded that this was due to the pharmacokinetic properties of budesonide[40].

A study was conducted to evaluate the efficacy and safety of BDP enemas versus prednisone enemas in active distal UC after 1 month of treatment. They determined that clinical and endoscopic remission occurred in 29% of patients who received BDP and in 25% of patients who had standard topical GC treatment, and both groups experienced few adverse effects[41]. This evidence leads to the conclusion that BDP has similar efficacy to traditional GCs.

***GC delivery technology, the next step to avoid side effects***

Novel drug delivery systems capable of slowly releasing drugs into the bloodstream at a low concentration such as the erythrocyte-mediated drug delivery have been proposed. The membrane characteristics of autologous erythrocytes render them ideal drug carriers because their permeability allows for the diffusion of small molecules. This has been demonstrated using dexamethasone 21-phosphate (Dex 21-P), a biologically inactive compound[42]. Once encapsulated, an enzyme resident in the red blood cell dephosphorylates Dex 21-P to form the corresponding active metabolite, dexamethasone (Dex), which is then released into the bloodstream by passive diffusion through the cytoplasmic membrane of erythrocytes[42].

A study recruited 40 patients with mild to moderate UC, who had not responded to mesalamine and randomly assigned them to one of the following three treatment groups: Dex 21-P encapsulated into erythrocytes (DEE) delivered *via* two infusions 14 d apart, oral prednisolone infusions (0.5 mg/kg for 2 wk by 6 mg/wk tapering), and placebo. The group of DEE and oral prednisolone achieved a higher rate of clinical and endoscopic remission (75%) after 2 mo compared to placebo[42]. DEE-treated patients showed no adverse effects associated with GCs, in contrast to 80% of prednisone group, in whom acne, hirsutism and weight gain were reported. This delivery tool is an attractive choice for patients with IBDs to avoid most of GCs’ adverse effects.

***Resistance and dependence, an unresolved issue for GC treatment***

More than half of IBDs patients on GC therapy respond to treatment, approximately 28% have a partial response, and 19% are non-responders (GC-resistant). However, about 20% of IBDs patients on long-term GC therapy become dependent[43,44]. Therefore, clarifying this GC resistance/dependency is crucial to making appropriate decisions regarding patient treatment. GC resistance or refractoriness is the inability of GCs to exert their effects on target tissues, thus limiting the efficacy of the therapy. In IBDs, GC resistance is defined as the persistence of an active manifestation of the pathology, despite having received standard treatment of 0.75 mg/kg per day for 4 or more weeks[44].

On the other hand, GC dependency is the need for GCs to maintain remission. Patients are considered GC-dependent if they fail to taper to steroid doses below 10 mg within 4 months (starting dose 0.75–1 mg/kg oral prednisone-equivalent) or if they relapse within 3 months after the discontinuation of GC treatment. Usually, long-term treatment with GCs is associated with its resistance or dependency and a more aggressive clinical phenotype in IBD patients[45].

**MOLECULAR BASIS OF GLUCOCORTICOID TREATMENT**

Exogenous GCs are highly lipophilic compounds, making them widely bioavailable. Similar to endogenous cortisol, GCs are primarily transported in the bloodstream bound to corticosteroid-binding globulin and, to a lesser extent, to albumin[46]. GCs have the ability to passively diffuse through cell membranes and interact with the glucocorticoid receptor (GR), a member of the nuclear receptor superfamily of ligand-dependent transcription factors[47].

***Molecular characteristics of GR and its impact on Immune system***

GR is a cytosolic protein with a molecular weight of 94 kDa encoded by the *NR3C1* gene (5q31.3). It contains nine exons that mainly code for two transcripts formed by alternative splicing: the α and β isoforms[48]. In addition to GRβ, three less-well-characterized isoforms have been reported: GRγ, GR-A and GR-P[49]. Moreover, GRα and GRβ can also undergo alternative translation initiation in exon 2, which generates eight additional GR isoforms with truncated N-terminals giving them distinct properties[49].

The amino terminal region of GRα contains a ligand-independent transactivation domain (AF-1), a highly conserved central DNA binding domain (DBD), and a hinge segment. The carboxyl-terminal region contains the ligand-binding domain (LBD), which includes an AF-2 region that interacts with co-regulators in a ligand-dependent manner[50]. The GRβ is a shorter protein which differs from GRα in its C-terminal domain and antagonizes the activity of GRα[51]. After GC binding, the receptors undergo conformational changes and expose the DBD, interact with chromatin, and regulate gene expression[50].

The GR-GC complex can inhibit proinflammatory proteins such as nuclear factor κB (NF-κB) and AP-1 through protein-protein interactions. These molecular mechanisms down-regulate the expression of proinflammatory cytokines and chemokines, such as IL-1α, IL-1β and IL-8. In addition, GCs up-regulate the expression of other cytokines that suppress the production of inflammatory mediators: such as transforming growth factor-β3 (TGF-β) and IL-10, increasing its anti-inflammatory function. They also inhibit T and B lymphocyte proliferation, and promote a tolerant macrophage profile (M2) (Figure 1)[46,52,53].

***Molecular basis of GC resistance, a clue for personalized treatment***

The molecular mechanisms of GC resistance in IBDs have been associated with changes in the GR isoform levels, polymorphisms in *NR3C1* or genes involved in GC bioavailability, and impaired cytokine production[46,48,54,55]. The most important genes associated to GC resistance are summarized in Table 2. Changes in levels of GRα and β isoforms have been associated with GC resistance. The α-isoform is the most well-studied protein, but only increased levels of the β-isoform have been associated to GC resistance in clinical trials in UC, asthma, nasal polyposis, cancer and chronic lymphocytic leukemia[53]. The GRβ protein is located primarily in the nucleus and is found mostly in T lymphocytes, macrophages, neutrophils, eosinophils, and peripheral blood mononuclear cells; however, it has also been reported in brain, lung, and heart tissue[56,57]. It has been proposed that GRβ may act as a dominant negative to GRα, since GRβ does not bind to GCs, but rather it interacts with glucocorticoid element response (GRE) causing GC resistance. This mechanism alters GRα signaling independent of GRα-GRβ heterodimer formation[58]. An *in vitro* study showed that overexpression of GRβ in a colonocyte cell model induces a vast deregulation of gene expression without Dex treatment, and a proportion of these genes have been shown to be altered in IBDs patients[59]. Thus, GRβ may directly change transcriptional gene activity of proinflammatory molecules. This effect is independent of GRα function and may promote the GC-resistance.

Furthermore, GRβ can bind to RU-486, a GRα antagonist, in such a way as to change the cellular location of this GRα, and alter its ability to regulate gene expression[60]. In addition, it has previously been shown that the expression of GRβ can be transcriptionally activated in regulatory T lymphocytes and neutrophils by proinflammatory cytokines[61]. Hence, GRβ expression may affect the immune response of these cells promoting inflammation and non-response to GC[55,57,62].

In 2009, a study was conducted to measure the expression of GRβ in intestinal mucosa of IBD patients that were refractory to treatment with GCs[55]. High levels of the GRα isoform were found in both GC-resistant and responsive patients; however, GC-resistant patients expressed higher levels of GRβ, in comparison with the GC-responder group. In the intestinal mucosa, the cells that primarily expressed the GRβ receptor were CD4+ and CD8+T lymphocytes, macrophages and B cells. Fibroblasts and vascular endothelial cells expressed GRβ in a minor proportion. These results suggest that a higher ratio of GRβ/GRα in inflammatory mononuclear cells disturbs the effects of GCs resulting in refractory outcomes.

Single nucleotide polymorphisms (SNPs) in *NR3C1* gene*,* have been associated with GC resistance[54], and these SNPs may result in different effects on the receptor structure and its signal transduction[54]. The most-studied SNPs that could induce a refractory phenotype in IBDs patients are: ER22/23EK (rs6189 and rs6190), N363S (rs6195), and BcII (rs41423247)[54]. The ER22/23EK is produced by a change in the amino acid residues 22 and 23 in the GR, where two glutamic acids (E) are replaced by an arginine (R) in position 22, and a lysine (K) in position 23[63]. These SNPs affect the transactivation process in *in vitro* assays, where the receptor is less likely to change its conformation and induce gene transcription in the presence of GCs[64]. The SNP N363S is in codon 363 of exon 2 and results in an amino acid change from asparagine (N) to serine (S). This SNP was reported to be associated with enhanced sensitivity to GCs, as was demonstrated by a Dex suppression test[65]. The BclI SNP was identified as a cytosine-guanine substitution 646 nucleotides downstream from exon 2, yielding 2.2 and 3.9 kb long fragments[63], which could suggest alternative splicing. A meta-analysis that included a mostly Caucasian population, analyzed the association of each of these 3 SNPs with GC resistance in IBDs patients[54]. Although no association was found, the analysis of the presence of all three SNPs, (or combinations of two SNPs) as a polygenic additive effect, could show risk associations of these variants with GC resistance.

Like the GR, the P-glycoprotein (P-gp) has also been associated with GC resistance in IBDs. P-gp is a trans-membrane glycoprotein with a molecular weight of 170 kDa encoded by the *MDR1* gene, which is located on the long arm of chromosome 7. P-gp is responsible for the absorption, distribution, metabolism and excretion of various drugs including GC[66]. A relationship between increased P-gp levels in circulating lymphocytes and intestinal epithelial cells with GC-resistant IBDs patients has been reported[67]. Polymorphisms in the *MDR1* gene have been shown to alter P-gp function, which in turn modifies the response to GCs[67]. A case-control study in a Brazilian population demonstrated that SNP C3435T (rs1045642), located in exon 26 of *MDR1* was associated with GC resistance in CD but not in UC patients[68].

Additionally, higher expression of proinflammatory cytokines has been associated with GC resistance. Overexpression of IL-6 and IL-8 has been associated with non-responsiveness to GC treatment[69]. In pediatric patients with UC, a similar correlation was found between the expression levels of IL-6 and unresponsiveness to GC[70]. In this study, the patients who did not respond to GC had higher levels of IL-6, compared to responders. Given the pleiotropic nature of IL-6, this correlation could reflect a cause-effect relationship between the signaling of the GC receptor and the expression of proinflammatory cytokines, but the real reason for the failure to respond remains unclear[70].

Similarly, in CD a correlation between cytokine production and resistance to GC was found. A clinical study showed that in intestinal mucosa from GC-resistant patients, the rate of apoptosis of T and B cells, presence of caspase-3 and IL-10 production were diminished compared to healthy and GC-responsive individuals[71]. These findings suggest a strong relationship between cytokine signaling and the inhibition of the GR effect in inflammatory diseases.

Analyses of gene expression using microarrays have been conducted to associate gene deregulation with GC resistance from colonoscopic biopsies of IBDs patients. ATG16L1, a gene related to the autophagy process was down-regulated in GC-resistant patients[72]. A low expression of the ATG16L1 protein has been associated with altered secretion of mucus by Paneth cells[73]. Furthermore, inhibition of autophagy led to Dex-resistance in a lymphoma cell line and in a mouse model[74]. This evidence indicates the importance of autophagy in the GC-resistant phenotype.

***GC dependence: another genetic issue***

Contrary to GC refractoriness, the molecular mechanisms behind GC dependence are poorly studied. There is evidence that associates *MDR1* SNPs (rs1128503 and rs1045642) with GC-dependent CD patients in a Chinese population[75]. Both SNPs correspond to a change from cytosine (C) to thymine (T) and are in coding regions of the gene (exon 12 and 26, respectively). Based on computational protein analysis, these SNPs, as haplotypes, seem to affect protein folding which could alter P-gp levels[76], but this mechanism has not been experimentally demonstrated. Nevertheless, the rs1045642 - CC was frequently found in individuals with significantly higher P-gp levels in plasma along with increased protein activity (measured by rhodamine efflux in CD56+ natural killer cells), compared to carriers of the TT genotype[77]. This study suggests that increased GC transportation out of cells might drive a decreased GC response leading to the dependent phenotype[75]

SNPs in the IL-10 gene have been associated with GC dependency as well. The SNP -1082 A/G (rs1800896) is located in the promoter sequence of the IL-10 gene, and a case control study of this variant showed an association with GC dependence in UC and CD patients[45]. This SNP was also related to a lower production of IL-10 in IBDs patients. Together, this evidence suggests that intrinsically inferior levels of IL-10 may generate GC dependency because exogenous GCs would be necessary to reach the anti-inflammatory IL-10 content necessary to achieve sustained remission. Other mechanisms, similar to those of refractoriness, such as altered expression of GR that impair intracellular signaling, have been proposed[78].

Downregulation of EBF3 was related to GC dependence in IBD patients[72]. The transcription factor EBF3 is a downstream target of SMAD2/3, which are components of the transforming growth factor-β (TGF-β) signaling pathway[79]. This anti-inflammatory mechanism might be impaired in the context of low EBF3 expression[80]. Moreover, EFB3 down-regulation has been associated with a low rate of apoptosis and increased cell proliferation[81]. This evidence suggests that decreased EBF3 levels might allow for a more severely inflamed phenotype making necessary a continual GC administration to maintain remission in IBD patients and driving their dependence.

***Epigenetics knowledge in GCs dependence/resistance in IBDs***

Epigenetic changes may also cause GC dependence/resistance. In the context of IBDs, higher methylation of the *Protease-Activated Receptor 2* (*PAR2*) gene, has been associated with steroid-dependent and resistance phenotypes in UC patients[82]. PAR2 is a G protein coupled receptor that is involved in pro-inflammatory responses and play a role in IBDs pathogenesis[82]. However, its specific role in GCs dependence/resistance has not been described.

Various studies relate the epigenetics changes such as hypermethylation of promoter genes with severe disease and risk of neoplasia[83–85]. There is evidence that epigenetic shifts can occur in the early stages of embryonic development in genes known us metastable epialleles (MEs), and this events can appear, as shown in rat and murine models, by environmental factors such as stress[86–88]. However, more analyses are needed to clarify the role of epigenetics in controlling the molecular mechanisms that underlie dependence or resistant to GCs in IBDs patients.

**CONCLUSION**

It has been over half a century since the first use of GC in IBD, yet amazingly, it currently remains a widely used therapeutic tool, specifically in disease exacerbations. The latest pharmacological applications, known as second-generation steroids, have contributed to the reduction of adverse reactions, however, increased effectiveness would need to be demonstrated in order for them to replace traditional GC therapy.

Despite findings showing positive GC responses, some patients remain resistant or become dependent to this drug. Deepening our understanding of the molecular basis of these undesired effects will help us generate novel, personalized GC therapies, depending on a patient’s genetic background and cytokine profiles.

**REFERENCES**

1 **Ananthakrishnan AN**. Environmental risk factors for inflammatory bowel diseases: a review. *Dig Dis Sci* 2015; **60**: 290-298 [PMID: 25204669 DOI: 10.1007/s10620-014-3350-9]

2 **Rietdijk ST**, D'Haens GR. Recent developments in the treatment of inflammatory bowel disease. *J Dig Dis* 2013; **14**: 282-287 [PMID: 23419117 DOI: 10.1111/1751-2980.12048]

3 **De Cassan C**, Fiorino G, Danese S. Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects? *Dig Dis* 2012; **30**: 368-375 [PMID: 22796798 DOI: 10.1159/000338128]

4 **Molodecky NA,** Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology* 2012; **142**: 46-54 [PMID: 22001864 DOI: 10.1053/j.gastro.2011.10.001]

5 **Simian D**, Fluxá D, Flores L, Lubascher J, Ibáñez P, Figueroa C, Kronberg U, Acuña R, Moreno M, Quera R. Inflammatory bowel disease: A descriptive study of 716 local Chilean patients. *World J Gastroenterol* 2016; **22**: 5267-5275 [PMID: 27298570 DOI: 10.3748/wjg.v22.i22.5267]

6 **Victoria CR**, Sassak LY, Nunes HR. Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of São Paulo State, Brazil. *Arq Gastroenterol* 2009; **46**: 20-25 [PMID: 19466305 DOI: 10.1590/S0004-28032009000100009]

7 **Abu Freha N**, Schwartz D, Elkrinawi J, Ben Yakov G, Abu Tailakh M, Munteanu D, Abu Ganim A, Fich A. Inflammatory bowel disease among Bedouin Arabs in southern Israel: urbanization and increasing prevalence rates. *Eur J Gastroenterol Hepatol* 2015; **27**: 230-234 [PMID: 25563139 DOI: 10.1097/MEG.0000000000000263]

8 **Hilmi I**, Jaya F, Chua A, Heng WC, Singh H, Goh KL. A first study on the incidence and prevalence of IBD in Malaysia--results from the Kinta Valley IBD Epidemiology Study. *J Crohns Colitis* 2015; **9**: 404-409 [PMID: 25744112 DOI: 10.1093/ecco-jcc/jjv039]

9 **Khor B,** Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. *Nature* 2011; **474**: 307–317 [PMID: 21677747 DOI: 10.1038/nature10209]

10 **Glocker EO**, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, Hätscher N, Pfeifer D, Sykora KW, Sauer M, Kreipe H, Lacher M, Nustede R, Woellner C, Baumann U, Salzer U, Koletzko S, Shah N, Segal AW, Sauerbrey A, Buderus S, Snapper SB, Grimbacher B, Klein C. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. *N Engl J Med* 2009; **361**: 2033-2045 [PMID: 19890111 DOI: 10.1056/NEJMoa0907206]

11 **Di Meglio P**, Di Cesare A, Laggner U, Chu CC, Napolitano L, Villanova F, Tosi I, Capon F, Trembath RC, Peris K, Nestle FO. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. *PLoS One* 2011; **6**: e17160 [PMID: 21364948 DOI: 10.1371/journal.pone.0017160]

12 **Pappa HM**, Langereis EJ, Grand RJ, Gordon CM. Prevalence and risk factors for hypovitaminosis D in young patients with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr* 2011; **53**: 361-364 [PMID: 21613964 DOI: 10.1097/MPG.0b013e3182250b3e]

13 **Loftus EV**. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. *Gastroenterology* 2004; **126**: 1504–1517 [PMID: 15168363 DOI: 10.1053/j.gastro.2004.01.063]

14 **Sartor RB,** Mazmanian SK. Intestinal Microbes in Inflammatory Bowel Diseases. *Am J Gastroenterol Suppl* 2012; **1**: 15–21 [DOI: 10.1038/ajgsup.2012.4]

15 **Frank DN**, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proc Natl Acad Sci U S A* 2007; **104**: 13780-13785 [PMID: 17699621 DOI: 10.1073/pnas.0706625104]

16 **Leitner GC**, Vogelsang H. Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. *World J Gastrointest Pharmacol Ther* 2016; **7**: 5-20 [PMID: 26855808 DOI: 10.4292/wjgpt.v7.i1.5]

17 **Kozuch PL**, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. *World J Gastroenterol* 2008; **14**: 354-377 [PMID: 18200659 DOI: 10.3748/wjg.14.354]

18 **TRUELOVE SC**, WITTS LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. *Br Med J* 1955; **2**: 1041-1048 [PMID: 13260656 DOI: 10.1159/000199983]

19 **Ford AC**, Bernstein CN, Khan KJ, Abreu MT, Marshall JK, Talley NJ, Moayyedi P. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. *Am J Gastroenterol* 2011; **106**: 590-59; quiz 600 [PMID: 21407179 DOI: 10.1038/ajg.2011.70]

20 **Danese S,** Hart A, Dignass A, Louis E, D’Haens G, Dotan I, Rogler G, D’Agay L, Iannacone C, Peyrin-Biroulet L. Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. *BMJ Open Gastroenterol* 2016; **3**: e000092 [PMID: 27239329 DOI: 10.1136/bmjgast-2016-000092]

21 **Sherlock ME**, MacDonald JK, Griffiths AM, Steinhart AH, Seow CH. Oral budesonide for induction of remission in ulcerative colitis. *Cochrane Database Syst Rev* 2015; **(10):** CD007698 [PMID: 26497719 DOI: 10.1002/14651858.CD007698]

22 **Paine ER**. Colonoscopic evaluation in ulcerative colitis. *Gastroenterol Rep* (Oxf) 2014; **2**: 161-168 [PMID: 24879406 DOI: 10.1093/gastro/gou028]

23 **Best WR**, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. *Gastroenterology* 1976; **70**: 439-444 [PMID: 1248701 DOI: 10.1016/S0016-5085(76)80163-1]

24 **Harvey RF**, Bradshaw JM. A simple index of Crohn's-disease activity. *Lancet* 1980; **1**: 514 [PMID: 6102236 DOI: 10.1016/S0140-6736(80)92767-1]

25 **Summers RW**, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F, Singleton JW. National Cooperative Crohn's Disease Study: results of drug treatment. *Gastroenterology* 1979; **77**: 847-869 [PMID: 38176]

26 **Malchow H**, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. *Gastroenterology* 1984; **86**: 249-266 [PMID: 6140202 DOI: 10.1016/S0022-3468(84)80296-1]

27 **Modigliani R,** Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, Rene E. Picture of attacks of Crohn’s evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. *Gastroenterology* 1990; **98**: 811-818 [PMID: 2179031 DOI: 10.1016/0016-5085(90)90002-I]

28 **Truelove SC**, Watkinson G, Draper G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. *Br Med J* 1962; **2**: 1708-1711 [PMID: 13994348 DOI: 10.1136/bmj.2.5321.1708]

29 **Lennard-jones JE**, Longmore AJ, Newell AC, Wilson CW, Jones FA. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. *Gut* 1960; **1**: 217-222 [PMID: 13760840 DOI: 10.1136/gut.1.3.217]

30 **Principi M**, Mastrolonardo M, Scicchitano P, Gesualdo M, Sassara M, Guida P, Bucci A, Zito A, Caputo P, Albano F, Ierardi E, Di Leo A, Ciccone MM. Endothelial function and cardiovascular risk in active inflammatory bowel diseases. *J Crohns Colitis* 2013; **7**: e427-e433 [PMID: 23473915 DOI: 10.1016/j.crohns.2013.02.001]

31 **Ho GT**, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. *Aliment Pharmacol Ther* 2006; **24**: 319-330 [PMID: 16842459 DOI: 10.1111/j.1365-2036.2006.02974.x]

32 **Greenberg GR**, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. *N Engl J Med* 1994; **331**: 836-841 [PMID: 8078529 DOI: 10.1056/NEJM199409293311303]

33 **Bar-Meir S**, Chowers Y, Lavy A, Abramovitch D, Sternberg A, Leichtmann G, Reshef R, Odes S, Moshkovitz M, Bruck R, Eliakim R, Maoz E, Mittmann U. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. *Gastroenterology* 1998; **115**: 835-840 [PMID: 9753485 DOI: 10.1016/S0016-5085(98)70254-9]

34 **Tremaine WJ**, Hanauer SB, Katz S, Winston BD, Levine JG, Persson T, Persson A. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. *Am J Gastroenterol* 2002; **97**: 1748-1754 [PMID: 12135030 DOI: 10.1111/j.1572-0241.2002.05835.x]

35 **Rezaie A**, Kuenzig ME, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH, Kaplan GG, Seow CH. Budesonide for induction of remission in Crohn's disease. *Cochrane Database Syst Rev* 2015;**(6):** CD000296 [PMID: 26039678 DOI: 10.1002/14651858.CD000296.pub4]

36 **Sandborn WJ**, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. *Gastroenterology* 2012; **143**: 1218-26.e1-2 [PMID: 22892337 DOI: 10.1053/j.gastro.2012.08.003]

37 **Danese S**, Siegel CA, Peyrin-Biroulet L. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. *Aliment Pharmacol Ther* 2014; **39**: 1095-1103 [PMID: 24641622 DOI: 10.1111/apt.12712]

38 **Lichtenstein GR**, Travis S, Danese S, D'Haens G, Moro L, Jones R, Huang M, Ballard ED, Bagin R, Hardiman Y, Collazo R, Sandborn WJ. Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. *J Crohns Colitis* 2015; **9**: 738-746 [PMID: 26094251 DOI: 10.1093/ecco-jcc/jjv101]

39 **Prantera C**, Marconi S. Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity. *Therap Adv Gastroenterol* 2013; **6**: 137-156 [PMID: 23503968 DOI: 10.1177/1756283X12473675]

40 **Tursi A**, Giorgetti GM, Brandimarte G, Elisei W, Aiello F. Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn's disease: an open-label, budesonide-controlled, randomized study. *Med Sci Monit* 2006; **12**: PI29-PI32 [PMID: 16733496]

41 **Campieri M**, Cottone M, Miglio F, Manenti F, Astegiano M, D'Arienzo A, Manguso F, D'Albasio G, Bonanomi A, Galeazzi R, Orlando A, Castiglione GN, Gionchetti P. Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis. *Aliment Pharmacol Ther* 1998; **12**: 361-366 [PMID: 9690726 DOI: 10.1046/j.1365-2036.1998.00299.x]

42 **Bossa F**, Latiano A, Rossi L, Magnani M, Palmieri O, Dallapiccola B, Serafini S, Damonte G, De Santo E, Andriulli A, Annese V. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. *Am J Gastroenterol* 2008; **103**: 2509-2516 [PMID: 18721243 DOI: 10.1111/j.1572-0241.2008.02103.x]

43 **Faubion WA**, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. *Gastroenterology* 2001; **121**: 255-260 [PMID: 11487534 DOI: 10.1053/gast.2001.26279]

44 **Manz M**, Vavricka SR, Wanner R, Lakatos PL, Rogler G, Frei P, Safroneeva E, Schoepfer AM. Therapy of steroid-resistant inflammatory bowel disease. *Digestion* 2012; **86** Suppl 1: 11-15 [PMID: 23051721 DOI: 10.1159/000341952]

45 **Castro-Santos P**, Suarez A, López-Rivas L, Mozo L, Gutierrez C. TNFalpha and IL-10 gene polymorphisms in inflammatory bowel disease. Association of -1082 AA low producer IL-10 genotype with steroid dependency. *Am J Gastroenterol* 2006; **101**: 1039-1047 [PMID: 16573780 DOI: 10.1111/j.1572-0241.2006.00501.x]

46 **De Iudicibus S**, Franca R, Martelossi S, Ventura A, Decorti G. Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. *World J Gastroenterol* 2011; **17**: 1095-1108 [PMID: 21448414 DOI: 10.3748/wjg.v17.i9.1095]

47 **Lu NZ**, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel NL, Wilson EM, McDonnell DP, Cidlowski JA. International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. *Pharmacol Rev* 2006; **58**: 782-797 [PMID: 17132855 DOI: 10.1124/pr.58.4.9]

48 **Hollenberg SM**, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, Thompson EB, Rosenfeld MG, Evans RM. Primary structure and expression of a functional human glucocorticoid receptor cDNA. *Nature* 1985; **318**: 635-641 [PMID: 2867473 DOI: 10.1038/318635a0]

49 **Oakley RH**, Cidlowski JA. Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissue-specific actions of glucocorticoids. *J Biol Chem* 2011; **286**: 3177-3184 [PMID: 21149445 DOI: 10.1074/jbc.R110.179325]

50 **Chrousos GP**, Kino T. Intracellular glucocorticoid signaling: a formerly simple system turns stochastic. *Sci STKE* 2005; **2005**: pe48 [PMID: 16204701 DOI: 10.1126/stke.3042005pe48]

51 **Kino T**, Su YA, Chrousos GP. Human glucocorticoid receptor isoform beta: recent understanding of its potential implications in physiology and pathophysiology. *Cell Mol Life Sci* 2009; **66**: 3435-3448 [PMID: 19633971 DOI: 10.1007/s00018-009-0098-z]

52 **Almawi WY**, Melemedjian OK. Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. *J Leukoc Biol* 2002; **71**: 9-15 [PMID: 11781376]

53 **Gross KL**, Cidlowski JA. Tissue-specific glucocorticoid action: a family affair. *Trends Endocrinol Metab* 2008; **19**: 331-339 [PMID: 18805703 DOI: 10.1016/j.tem.2008.07.009]

54 **Chen HL**, Li LR. Glucocorticoid receptor gene polymorphisms and glucocorticoid resistance in inflammatory bowel disease: a meta-analysis. *Dig Dis Sci* 2012; **57**: 3065-3075 [PMID: 22752665 DOI: 10.1007/s10620-012-2293-2]

55 **Fujishima S**, Takeda H, Kawata S, Yamakawa M. The relationship between the expression of the glucocorticoid receptor in biopsied colonic mucosa and the glucocorticoid responsiveness of ulcerative colitis patients. *Clin Immunol* 2009; **133**: 208-217 [PMID: 19646928 DOI: 10.1016/j.clim.2009.07.006]

56 **Oakley RH**, Webster JC, Sar M, Parker CR, Cidlowski JA. Expression and subcellular distribution of the beta-isoform of the human glucocorticoid receptor. *Endocrinology* 1997; **138**: 5028-5038 [PMID: 9348235 DOI: 10.1210/endo.138.11.5501]

57 **Pujols L**, Mullol J, Roca-Ferrer J, Torrego A, Xaubet A, Cidlowski JA, Picado C. Expression of glucocorticoid receptor alpha- and beta-isoforms in human cells and tissues. *Am J Physiol Cell Physiol* 2002; **283**: C1324-C1331 [PMID: 12225995 DOI: 10.1152/ajpcell.00363.2001]

58 **Oakley RH**, Sar M, Cidlowski JA. The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function. *J Biol Chem* 1996; **271**: 9550-9559 [PMID: 8621628 DOI: 10.1074/jbc.271.16.9550]

59 **Nagy Z**, Acs B, Butz H, Feldman K, Marta A, Szabo PM, Baghy K, Pazmany T, Racz K, Liko I, Patocs A. Overexpression of GRß in colonic mucosal cell line partly reflects altered gene expression in colonic mucosa of patients with inflammatory bowel disease. *J Steroid Biochem Mol Biol* 2016; **155**: 76-84 [PMID: 26480216 DOI: 10.1016/j.jsbmb.2015.10.006]

60 **Lewis-Tuffin LJ**, Jewell CM, Bienstock RJ, Collins JB, Cidlowski JA. Human glucocorticoid receptor beta binds RU-486 and is transcriptionally active. *Mol Cell Biol* 2007; **27**: 2266-2282 [PMID: 17242213 DOI: 10.1128/MCB.01439-06]

61 **Webster JC**, Oakley RH, Jewell CM, Cidlowski JA. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance. *Proc Natl Acad Sci U S A* 2001; **98**: 6865-6870 [PMID: 11381138 DOI: 10.1073/pnas.121455098]

62 **Boivin MA**, Ye D, Kennedy JC, Al-Sadi R, Shepela C, Ma TY. Mechanism of glucocorticoid regulation of the intestinal tight junction barrier. *Am J Physiol Gastrointest Liver Physiol* 2007; **292**: G590-G598 [PMID: 17068119 DOI: 10.1152/ajpgi.00252.2006]

63 **van Rossum EFC**, Lamberts SWJ. Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. *Recent Prog Horm Res* 2004; **59**: 333–57 [PMID: 14749509 DOI: 10.1210/rp.59.1.333]

64 **Russcher H**, Smit P, van den Akker EL, van Rossum EF, Brinkmann AO, de Jong FH, Lamberts SW, Koper JW. Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression. *J Clin Endocrinol Metab* 2005; **90**: 5804-5810 [PMID: 16030164 DOI: 10.1210/jc.2005-0646]

65 **Marti A**, Ochoa MC, Sánchez-Villegas A, Martínez JA, Martínez-González MA, Hebebrand J, Hinney A, Vedder H. Meta-analysis on the effect of the N363S polymorphism of the glucocorticoid receptor gene (GRL) on human obesity. *BMC Med Genet* 2006; **7**: 50 [PMID: 16725041 DOI: 10.1186/1471-2350-7-50]

66 **Farrell RJ**, Menconi MJ, Keates AC, Kelly CP. P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes. *Aliment Pharmacol Ther* 2002; **16**: 1021-1031 [PMID: 11966513 DOI: 10.1046/j.1365-2036.2002.01238.x]

67 **Hoffmeyer S**, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. *Proc Natl Acad Sci U S A* 2000; **97**: 3473-3478 [PMID: 10716719 DOI: 10.1073/pnas.050585397]

68 **Carvalho AT**, Fróes RS, Esberard BC, Santos JC, Rapozo DC, Grinman AB, Simão TA, Nicolau Neto P, Luiz RR, Carneiro AJ, Souza HS, Ribeiro-Pinto LF. Multidrug resistance 1 gene polymorphisms may determine Crohn's disease behavior in patients from Rio de Janeiro. *Clinics* (Sao Paulo) 2014; **69**: 327-334 [PMID: 24838898 DOI: 10.6061/clinics/2014(05)06]

69 **Ishiguro Y**. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. *J Gastroenterol* 1999; **34**: 66-74 [PMID: 10204613 DOI: 10.1007/s005350050218]

70 **Wine E**, Mack DR, Hyams J, Otley AR, Markowitz J, Crandall WV, Leleiko N, Muise AM, Griffiths AM, Turner D. Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis. *J Crohns Colitis* 2013; **7**: 916-922 [PMID: 23339932 DOI: 10.1016/j.crohns.2012.12.012]

71 **Santaolalla R**, Mañé J, Pedrosa E, Lorén V, Fernández-Bañares F, Mallolas J, Carrasco A, Salas A, Rosinach M, Forné M, Espinós JC, Loras C, Donovan M, Puig P, Mañosa M, Gassull MA, Viver JM, Esteve M. Apoptosis resistance of mucosal lymphocytes and IL-10 deficiency in patients with steroid-refractory Crohn's disease. *Inflamm Bowel Dis* 2011; **17**: 1490-1500 [PMID: 21674705 DOI: 10.1002/ibd.21507]

72 **Montero-Meléndez T**, Llor X, García-Planella E, Perretti M, Suárez A. Identification of novel predictor classifiers for inflammatory bowel disease by gene expression profiling. *PLoS One* 2013; **8**: e76235 [PMID: 24155895 DOI: 10.1371/journal.pone.0076235]

73 **Cadwell K**, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK, Kishi C, Kc W, Carrero JA, Hunt S, Stone CD, Brunt EM, Xavier RJ, Sleckman BP, Li E, Mizushima N, Stappenbeck TS, Virgin HW. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. *Nature* 2008; **456**: 259-263 [PMID: 18849966 DOI: 10.1038/nature07416]

74 **Jiang L**, Xu L, Xie J, Li S, Guan Y, Zhang Y, Hou Z, Guo T, Shu X, Wang C, Fan W, Si Y, Yang Y, Kang Z, Fang M, Liu Q. Inhibition of autophagy overcomes glucocorticoid resistance in lymphoid malignant cells. *Cancer Biol Ther* 2015; **16**: 466-476 [PMID: 25778879 DOI: 10.1080/15384047.2015.1016658]

75 **Yang QF**, Chen BL, Zhang QS, Zhu ZH, Hu B, He Y, Gao X, Wang YM, Hu PJ, Chen MH, Zeng ZR. Contribution of MDR1 gene polymorphisms on IBD predisposition and response to glucocorticoids in IBD in a Chinese population. *J Dig Dis* 2015; **16**: 22-30 [PMID: 25346426 DOI: 10.1111/1751-2980.12205]

76 **Fung KL**, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. *Biochim Biophys Acta* 2009; **1794**: 860-871 [PMID: 19285158 DOI: 10.1016/j.bbapap.2009.02.014]

77 **Hitzl M**, Drescher S, van der Kuip H, Schäffeler E, Fischer J, Schwab M, Eichelbaum M, Fromm MF. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. *Pharmacogenetics* 2001; **11**: 293-298 [PMID: 11434506 DOI: 10.1097/00008571-200106000-00003]

78 **Chikanza IC**, Kozaci D, Chernajovsky Y. The molecular and cellular basis of corticosteroid resistance. *J Endocrinol* 2003; **179**: 301-310 [PMID: 14656201 DOI: 10.1677/joe.0.1790301]

79 **Bond HM**, Mesuraca M, Amodio N, Mega T, Agosti V, Fanello D, Pelaggi D, Bullinger L, Grieco M, Moore MA, Venuta S, Morrone G. Early hematopoietic zinc finger protein-zinc finger protein 521: a candidate regulator of diverse immature cells. *Int J Biochem Cell Biol* 2008; **40**: 848-854 [PMID: 17543573 DOI: 10.1016/j.biocel.2007.04.006]

80 **Park SH**, Kim SK, Choe JY, Moon Y, An S, Park MJ, Kim DS. Hypermethylation of EBF3 and IRX1 genes in synovial fibroblasts of patients with rheumatoid arthritis. *Mol Cells* 2013; **35**: 298-304 [PMID: 23456299 DOI: 10.1007/s10059-013-2302-0]

81 **Zhao LY**, Niu Y, Santiago A, Liu J, Albert SH, Robertson KD, Liao D. An EBF3-mediated transcriptional program that induces cell cycle arrest and apoptosis. *Cancer Res* 2006; **66**: 9445-9452 [PMID: 17018599 DOI: 10.1158/0008-5472.CAN-06-1713]

82 **Tahara T**, Shibata T, Nakamura M, Yamashita H, Yoshioka D, Okubo M, Maruyama N, Kamano T, Kamiya Y, Fujita H, Nakagawa Y, Nagasaka M, Iwata M, Takahama K, Watanabe M, Nakano H, Hirata I, Arisawa T. Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC). *Clin Exp Med* 2009; **9**: 125-130 [PMID: 19184329 DOI: 10.1007/s10238-008-0025-x]

83 **Kuester D**, Guenther T, Biesold S, Hartmann A, Bataille F, Ruemmele P, Peters B, Meyer F, Schubert D, Bohr UR, Malfertheiner P, Lippert H, Silver AR, Roessner A, Schneider-Stock R. Aberrant methylation of DAPK in long-standing ulcerative colitis and ulcerative colitis-associated carcinoma. *Pathol Res Pract* 2010; **206**: 616-624 [PMID: 20630662 DOI: 10.1016/j.prp.2010.05.004]

84 **Balasa A**, Gathungu G, Kisfali P, Smith EO, Cho JH, Melegh B, Kellermayer R. Assessment of DNA methylation at the interferon regulatory factor 5 (IRF5) promoter region in inflammatory bowel diseases. *Int J Colorectal Dis* 2010; **25**: 553-556 [PMID: 20127100 DOI: 10.1007/s00384-010-0874-0]

85 **Sato F**, Harpaz N, Shibata D, Xu Y, Yin J, Mori Y, Zou TT, Wang S, Desai K, Leytin A, Selaru FM, Abraham JM, Meltzer SJ. Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. *Cancer Res* 2002; **62**: 1148-1151 [PMID: 11861396]

86 **Harris RA**, Nagy-Szakal D, Kellermayer R. Human metastable epiallele candidates link to common disorders. *Epigenetics* 2013; **8**: 157-163 [PMID: 23321599 DOI: 10.4161/epi.23438]

87 **Weinhouse C**, Anderson OS, Jones TR, Kim J, Liberman SA, Nahar MS, Rozek LS, Jirtle RL, Dolinoy DC. An expression microarray approach for the identification of metastable epialleles in the mouse genome. *Epigenetics* 2011; **6**: 1105-1113 [PMID: 21829099 DOI: 10.4161/epi.6.9.17103]

88 **Weaver IC**, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, Dymov S, Szyf M, Meaney MJ. Epigenetic programming by maternal behavior. *Nat Neurosci* 2004; **7**: 847-854 [PMID: 15220929 DOI: 10.1038/nn1276]

**P-Reviewer:** Ciccone MM, Quetglas EG **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Chile

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Glucocorticoids of first and second generation and his medical uses**

|  |  |  |  |
| --- | --- | --- | --- |
| Glucocorticoids | Component | Indications | Ref. |
| 1st generation | Prednisone Methyl-Prednisolone Hydrocortisone  | Moderate to Severe cases of IBDsShort duration of treatment  | [3,25,27][26][29] |
| 2nd generation | Budesonide Budesonide MMX Beclomethasone dipropionate Erythrocyte ­ Mediated Delivery of Dexamethasone  | Moderate CD cases Mild to moderate UC casesTopical administrationIn research for long term treatments | [32–34][36,37][40,41][42] |

**Table 2 Molecular highlights on responses to steroidal treatment**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Gene/****protein** | **Function** | **Molecular alteration or genetic variant** | **Effect on GC response** | **Ref.** |
| NR3C1 | GC receptor | Increased expression of the  isoform | Block signaling of the  isoform/GC resistance | [58] |
| rs6189rs6190 rs6195 | Altered transactivation of GC receptor/GC resistance Enhanced sensitivity to GC  | [54,63] [65] |
|  |  |  |
| rs41423247 | Alternative splicing of receptor/GC resistance  | [54,63] |
| MDR1 | Export of drugs from the cell | rs1045642 | Decreased MDR1 levels/ GC resistance in Brazilian CD patients | [68] |
| rs1128503rs1045642 | Possible misfolding/GC dependence in Chinese CD patients | [75–77] |
| IL-10 | Anti-inflammatory cytokine | rs1800896 | Lowered production of IL-10/GC dependence in UC and CD patients | [45] |
| EBF3PAR2 | Transcription factorG protein coupled receptor | Decreased levels of EBF3Methylation of gene promoter | More severely inflamed phenotype /GC dependenceGC resistance/dependence in UC patients. | [72][82] |

UC: Ulcerative colitis; CD: Crohn's disease; GCs: Glucocorticoids.



**Figure 1 Immunologic dynamics and the responses triggered by glucocorticoids in inflammatory bowel diseases.** During activation of the immune response in inflammatory bowel diseases (IBDs), the invasion of bacteria and the cytokine cascade triggered by the disruption of the epithelial barrier prompt an inflammatory response in the intestinal mucosa. Among the different cells that participate in the pathology of IBDs, the most important are represented in this diagram. When bacterial organisms interact with dendritic cells (DC), or the intestinal epithelium is disrupted due to an inflammatory response, the production of proinflammatory cytokines and the release of DAMPs (Damaged- Associated Molecular Patterns) such as TNF-α and IL-33, respectively, is elicited. This leads to the infiltration of immune cells such as monocytes which differentiate into proinflammatory M1 macrophages (Mø) and lymphocytes T (T cells), along with mast cell activation. In the presence of glucocorticoids (GCs), the infiltrating monocytes differentiate into a regulatory M2 profile Mø and CD103+ DCs. These tolerogenic cells produce anti-inflammatory cytokines, skew the infiltrating naïve T cells toward a T regulatory phenotype, and control the inflammatory response. Also, the action of GCs blocks the production of proinflammatory cytokines by the M1 Mø, T cells and DCs, leading to the healing of the intestinal mucosa.